Literature DB >> 9834226

Interleukin-6 (IL-6) prevents activation-induced cell death: IL-2-independent inhibition of Fas/fasL expression and cell death.

E Ayroldi1, O Zollo, L Cannarile, F D' Adamio, U Grohmann, D V Delfino, C Riccardi.   

Abstract

Triggering of the TCR/CD3 complex with specific antigen or anti-CD3 monoclonal antibody initiates activation-induced cell death (AICD) in mature T cells, an effect also mediated by the Fas/FasL system. We have previously shown that CD2 stimulation rescues T cells from TCR/CD3-induced apoptosis by decreasing the expression of Fas and FasL. In the present study, we examined whether the endogenous production of IL-2 plays a role in the effects mediated by CD2 triggering. The results indicated that transcription of Fas/FasL is controlled by interleukin-2 (IL-2) production and that CD2 triggering rescues a T-cell hybridoma from AICD via decreased production of IL-2. To ascertain whether modulation of IL-2 may be a general mechanism of AICD control, we examined other stimuli, capable of modulating the expression of the Fas/FasL system and the ensuing AICD, for ability to affect production of IL-2. We found that IL-6 reduced the level of TCR/CD3-induced apoptosis and the expression of Fas/FasL, yet failed to inhibit IL-2 production. Because IL-2 is involved in both apoptosis and activation events, these results indicate that, in contrast to CD2, which inhibits apoptosis and T cell activation, IL-6 inhibits apoptosis but not IL-2-induced activation. These observations may provide the basis for differential control of T-cell activation and apoptosis.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9834226

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  28 in total

1.  T helper lymphocytes rescue CTL from activation-induced cell death.

Authors:  Richard Kennedy; Esteban Celis
Journal:  J Immunol       Date:  2006-09-01       Impact factor: 5.422

Review 2.  Harnessing programmed cell death as a therapeutic strategy in rheumatic diseases.

Authors:  Madhu Ramaswamy; Min Deng; Richard M Siegel
Journal:  Nat Rev Rheumatol       Date:  2011-02-01       Impact factor: 20.543

3.  TRAF6 inhibits Th17 differentiation and TGF-beta-mediated suppression of IL-2.

Authors:  Pedro J Cejas; Matthew C Walsh; Erika L Pearce; Daehee Han; Gretchen M Harms; David Artis; Laurence A Turka; Yongwon Choi
Journal:  Blood       Date:  2010-03-29       Impact factor: 22.113

4.  T cells and stromal fibroblasts in human tumor microenvironments represent potential therapeutic targets.

Authors:  Jennifer L Barnas; Michelle R Simpson-Abelson; Sandra J Yokota; Raymond J Kelleher; Richard B Bankert
Journal:  Cancer Microenviron       Date:  2010-03-31

5.  IL-6 Promotes T Cell Proliferation and Expansion under Inflammatory Conditions in Association with Low-Level RORγt Expression.

Authors:  Bofeng Li; Lindsay L Jones; Terrence L Geiger
Journal:  J Immunol       Date:  2018-10-12       Impact factor: 5.422

6.  Induction and inhibition of apoptosis by pseudorabies virus in the trigeminal ganglion during acute infection of swine.

Authors:  N Alemañ; M I Quiroga; M López-Peña; S Vázquez; F H Guerrero; J M Nieto
Journal:  J Virol       Date:  2001-01       Impact factor: 5.103

7.  Anti-IL-6 receptor monoclonal antibody inhibits leukocyte recruitment and promotes T-cell apoptosis in a murine model of Crohn's disease.

Authors:  Hiroaki Ito; Tomonori Hirotani; Mitsunari Yamamoto; Hiroyuki Ogawa; Tadamitsu Kishimoto
Journal:  J Gastroenterol       Date:  2002-11       Impact factor: 7.527

8.  Characterizing a soluble survival signal for activated lymphocytes from CD14+ cells.

Authors:  Xiaolei Tang; David E Yocum; David DeJonghe; Kathy Nordensson
Journal:  Immunology       Date:  2002-09       Impact factor: 7.397

Review 9.  The effects of IL-6 on CD4 T cell responses.

Authors:  Oliver Dienz; Mercedes Rincon
Journal:  Clin Immunol       Date:  2008-10-08       Impact factor: 3.969

10.  Interleukin-6 expands homeostatic space for peripheral T cells.

Authors:  Changwan Hong; Anna S Nam; Hilary R Keller; Davinna L Ligons; Joo-Young Park; Hee-Won Yoon; Joseph J Park; Megan A Luckey; Jung-Hyun Park
Journal:  Cytokine       Date:  2013-08-26       Impact factor: 3.861

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.